CSL LIMITED's stock soared 5.02% during intraday trading on Friday, following positive regulatory news from the United Kingdom.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for CSL's adjuvanted trivalent influenza vaccine, AUJEMFLU. The approval allows the vaccine to be marketed to protect adults aged 50 and over against flu, potentially opening a significant new market for the company's product portfolio.